

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11

## Supporting Information

### **Hydrophilic magnetic MOF for consecutive enrichment of exosomes and exosomal phosphopeptides**

Ning Zhang,<sup>a</sup> Nianrong Sun\*<sup>b</sup> and Chunhui Deng\*<sup>a,b,c</sup>

<sup>a</sup>Department of Chemistry, Fudan University, Shanghai 200433, China

<sup>b</sup>Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai  
200032, China

<sup>c</sup>Institutes of Biomedical Sciences, and Collaborative Innovation Centre of Genetics and  
Development, Fudan University, Shanghai 200433, China

## 12 **Experiment section**

13 **Chemicals.** 20×TBS and 1×PBS were purchased from Solarbio. CD63 polyclonal  
14 antibody, anti-TSG101 polyclonal antibody and goat anti-rabbit IgG (HRP conjugated)  
15 were purchased from MultiSciences (Lianke) Biotech. CD9 polyclonal antibody, EPCAM  
16 monoclonal antibody and HRP-conjugated affinipure goat anti-mouse IgG were purchased  
17 from Proteintech. Sequencing grade trypsin was purchased from Promega. 1,1'-  
18 dioctadecyl-3,3,3',3'tetramethylindocarbocyanine perchlorate (DiI) were purchased from  
19 Meilun Biotechnology Company. Phosphotungstic acid hydrate were purchased from Alfa  
20 Aesar. Dithiothreitol (DTT), iodoacetamide (IAA), urea, thiourea, phenylmethanesulfonyl  
21 fluoride (PMSF), zirconium tetrachloride ( $ZrCl_4$ ), 2-aminoterephthalic acid ( $H_2BDC-$   
22  $NH_2$ ), N,N'-dimethylformamide (DMF), dopamine hydrochloride, tris(hydroxymethyl)-  
23 aminomethane (Tris), and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich.  
24 Iron chloride hexahydrate ( $FeCl_3 \cdot 6H_2O$ ), ethylene glycol, sodium acetate anhydrous and  
25 concentrated ammonia solution (28 wt%) were purchased from Guoyao Chemical Reagent  
26 Company. Acetonitrile (ACN) was purchased from Merck. Dulbecco's modified Eagle's  
27 medium (DMEM) and fetal bovine serum (FBS) were purchased from Thermo Scientific.

28 **Synthesis of  $Fe_3O_4@PDA@UIO-66-NH_2$ .** Generally speaking,  $FeCl_3 \cdot 6H_2O$  and  
29  $CH_3COONa$  were dispersed in 75 mL ethylene glycol to form  $Fe_3O_4$  nanoparticles via the  
30 solvo-thermal reaction. Then, the obtained  $Fe_3O_4$  was added into Tris buffer incorporating  
31 dopamine hydrochloride and  $Fe_3O_4@PDA$  was formed at room temperature. Finally,  
32  $Fe_3O_4@PDA@UIO-66-NH_2$  was synthesized by the one-pot reaction at 120 °C for 1 h, in

33 which Fe<sub>3</sub>O<sub>4</sub>@PDA, as the MOF precursor, was mixed with ZrCl<sub>4</sub> (9 mM) and H<sub>2</sub>BDC-  
34 NH<sub>2</sub> (9 mM) in 75 mL DMF.

35 **Cell culture.** MCF-7 cells were cultured in petri dishes (100 mm diameter, 20 mm height)  
36 with 10% FBS, 89.5% DMEM and 0.5% penicillin-streptomycin and set in a humidified  
37 incubator with 5% CO<sub>2</sub> at 37 °C. The above supernatant was instead by condition media  
38 without FBS since 80% bottom area of the petri dish was covered by MCF-7 cells. After  
39 incubation for 24 h, the late supernatant was collected to capture exosomes.

40 **Preparation of exosomes samples from MCF-7 cells and urine.** The collected  
41 supernatants of MCF-7 cells were filtered with filter (0.22 μm) to remove apoptotic blebs,  
42 cell debris, and cells. Then the filtrates were concentrated through an ultrafiltration tube  
43 (Merck Millipore, 100 kDa) and some proteins and peptides were removed together.  
44 Afterwards, the concentrate were dispersed in 1×TBS and stored at -80 °C for further use.

45 The urine samples were collected from healthy donors who provided written informed  
46 consent with prior approval of the ethics committee of the Shanghai Zhongshan Hospital.  
47 Firstly, urine samples were collected from 4 healthy volunteers (24-28 years old, 2 males  
48 and 2 females), and second morning mid-stream urine (approximately 100 mL) of each  
49 healthy volunteer was collected into 50-ml centrifuge tubes storing in the ice for an hour  
50 to promote some salt impurities precipitating. Secondly, the above samples were  
51 centrifuged at 2,000 g for 15 min and the supernatants were treated subsequently as same  
52 as above procedures of cell samples.

53 **Exosomes isolation.** First of all, 6.0 mg Fe<sub>3</sub>O<sub>4</sub>@PDA@UIO-66-NH<sub>2</sub> were incubated with

54 1 mL pre-treated MCF-7 cell samples at 4 °C for 10 min. Secondly, the supernatants were  
55 removed with the effect of magnet and the sediments were washed three times with PBS.  
56 Finally, the enriched exosomes were eluted by 0.4 M ammonia aqueous solution for 10  
57 min at 4 °C and the solvents were substituted by PBS with ultrafiltration tubes to keep  
58 exosomes activity. In addition, urinary exosomes were purified with the same process as  
59 above.

60 **Exosomes dye.** 40 µg purified exosomes secreted by MCF-7 cells was incubated in 1×TBS  
61 buffer containing 10 µM DiI and placed on the shaker at 37 °C for 15 min in the dark. After  
62 reacting with Fe<sub>3</sub>O<sub>4</sub>@PDA@UIO-66-NH<sub>2</sub>, the fluorescence intensity of supernatants and  
63 eluents were detected by fluorescence spectrometer (Hitachi, F-7000) at excitation and  
64 emission wavelengths of 545 nm and 570 nm to obtain the materials capture efficiency and  
65 exosomes recovery.

66 **Characterization of isolated exosomes.** Transmission electron microscopy. Exosomes  
67 suspended in PBS were dropped onto a 200-mesh formvar carbon coated copper grid and  
68 standing for 10 min. The excess solution was absorbed at the edge of the copper grid with  
69 the filter paper. Next, 2% phosphotungstic acid was dropped onto the above grid and  
70 incubated for 3 min to stain the exosomes samples. Then the grid was dried under the  
71 incandescent lamp and observed using a transmission electron microscope at 120  
72 KV(Hitachi, HT7700).

73 Western blot analysis. The protein concentration of samples were measured with  
74 Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific). Next, The 5× SDS-PAGE

75 protein loading buffer was added in the exosomes proteins samples separately and the  
76 samples were heated at 100 °C for 5 min to make proteins denatured. Then the proteins  
77 were resolved by electrophoresis using SDS-PAGE (WSHTbio, Hepes-Tris gel) and  
78 transferred onto a polyvinylidene fluoride (PVDF) microporous membrane (Merck  
79 Millipore Ltd., Immobilon-P Transfer Membrane) through the wet membrane transfer  
80 device. The PVDF membrane was rinsed and blocked with western blocking agent (Dalian  
81 Meilun Biotechnology Co. Ltd., China) for 1 h at room temperature. Next, the PVDF  
82 membrane was incubated with different antibody separately at 4 °C overnight. After  
83 rinsing, PVDF membrane was incubated with the secondary antibody labeled with HRP  
84 for 2 h. Lastly, blots were presented through ChemiDoc™ Touch Imaging System (Bio-  
85 Rad Laboratories, USA).

86 **Exosomes lysis and digestion.** Isolated exosomes were suspended in the urea lysis buffer  
87 containing 8 M urea, 2 M thiourea and 1 mM PMSF and ultrasonicated for 15 min. After  
88 centrifugation at 10,000 g for 5 min, the supernatant were substituted by 50 mM NH<sub>4</sub>HCO<sub>3</sub>  
89 buffer using ultrafiltration tubes (3 kDa). Following by heating for 10 min at 90 °C, the  
90 proteins were reduced by 10 mM DTT at 56 °C for 1 h and alkylated by 25 mM IAA in the  
91 dark at 37 °C for 0.5 h. Then trypsin was added in the samples (trypsin: protein=1:40, w/w),  
92 and incubated at 37 °C for 16 h. Finally, the peptides were collected after desalting and  
93 lyophilizing.

94 **Enrichment of urinary exosomes phosphopeptides.** Urinary exosomes phosphopeptides  
95 were dispersed in 100 µL 50%ACN/0.1%TFA (v/v) solution and 600 µg

96  $\text{Fe}_3\text{O}_4@\text{PDA}@\text{UIO-66-NH}_2$  were incubated in the mixture at 37 °C for 1 h to capture  
97 phosphopeptides. After washing by the above loading buffer to remove impurities, the goal  
98 peptides were eluted by 0.4 M ammonia aqueous solution for 45 min. Finally, through  
99 desalting and lyophilizing, eluents were analyzed by LC-MS/MS.


100 **LC-MS/MS analysis.** The peptides were resuspended with 10  $\mu\text{L}$  solvent A respectively  
101 (A: water with 0.1% formic acid; B: ACN with 0.1% formic acid), separated by nano-LC  
102 and analyzed by on-line electrospray tandem mass spectrometry. The experiments were  
103 performed on an EASY-nLC 1000 system (Thermo Fisher Scientific, Waltham, MA)  
104 connected to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, San Jose,  
105 CA) equipped with an online nano-electrospray ion source. 5  $\mu\text{L}$  peptide sample was loaded  
106 onto the analytical column (Acclaim PepMap C18, 75  $\mu\text{m} \times 25 \text{ cm}$ ), and subsequently  
107 separated with a linear gradient from 2% B to 90% B in 120 min. The column was re-  
108 equilibrated at initial conditions for 10 min. The column flow rate was maintained at 300  
109 nL/min. The electrospray voltage of 2.0 kV versus the inlet of the mass spectrometer was  
110 used.

111 The Orbitrap Fusion mass spectrometer was operated in the data-dependent mode to  
112 switch automatically between MS and MS/MS acquisition. Survey full-scan MS spectra  
113 ( $m/z$  350–1600) were acquired in Orbitrap with a mass resolution of 60,000 at  $m/z$  200.  
114 The AGC target was set to 500,000, and the maximum injection time was 50 ms. MS/MS  
115 acquisition was performed in Orbitrap with 3 s cycle time, the resolution was 15,000 at  $m/z$   
116 200. The intensity threshold was 50,000, and the maximum injection time was 100 ms. The

117 AGC target was set to 150,000, and the isolation window was 2 m/z. Ions with charge states  
118 2+, 3+, and 4+ were sequentially fragmented by higher energy collisional dissociation  
119 (HCD) with a normalized collision energy (NCE) of 30%, fixed first mass was set at 110.  
120 In all cases, one microscan was recorded using dynamic exclusion of 30 s.

121 MS/MS spectra were extracted by the Proteome Discoverer software (Thermo Fisher  
122 Scientific, version 1.4.0.288) with the MASCOT searching engine version 2.3.2. And the  
123 database was the Human UniProtKB/Swiss-Prot database (release 2018-01-26, with  
124 20,245 sequences). Raw files generated by the Orbitrap Fusion were searched directly  
125 using a 10-ppm precursor mass tolerance and a 20-ppm fragment mass tolerance. The  
126 enzyme specificity with trypsin was used. Up to two missed cleavages were allowed and  
127 peptides with at least six amino acids were retained. Carbamidomethyl on cysteine was set  
128 as a fixed modification. Oxidation on methionine and deamidation on asparagine were set  
129 as variable modifications. The FDRs were estimated by the program from the number and  
130 quality of spectral matches to the decoy database. For all data sets, the FDRs at spectrum,  
131 peptide, and protein level were < 1%.


132




134


Element Number	Element Symbol	Element Name	Atomic Conc.	Weight Conc.	
135	6	C	Carbon	37.37	18.56
	8	O	Oxygen	27.71	18.33
136	26	Fe	Iron	21.09	48.70
	7	N	Nitrogen	11.82	6.85
137	40	Zr	Zirconium	2.01	7.57

138 **Fig. S1.** Energy dispersive X-ray (EDX) spectrum data of  $\text{Fe}_3\text{O}_4@\text{PDA}@\text{UIO-66-NH}_2$ .






140




141

142 **Fig. S2.** Zeta potential of Fe<sub>3</sub>O<sub>4</sub> (a), Fe<sub>3</sub>O<sub>4</sub>@PDA (b) and Fe<sub>3</sub>O<sub>4</sub>@PDA@UIO-66-NH<sub>2</sub> (c).




143

144 **Fig. S3.** Magnetic hysteresis curves of  $\text{Fe}_3\text{O}_4@\text{PDA}@\text{UIO-66-NH}_2$ .



145


146 **Fig. S4.** Contact angle of (a)  $\text{Fe}_3\text{O}_4@\text{PDA}@\text{UIO-66-NH}_2$  and (b)  $\text{Fe}_3\text{O}_4@\text{PDA}@\text{UIO-66}$ .



147


148 **Fig. S5.** Nitrogen sorption isotherms and pore size distribution of Fe<sub>3</sub>O<sub>4</sub>@PDA@UIO-66-

149 NH<sub>2</sub>.




150

151 **Fig. S6.** Workflow of exosomes and phosphopeptides consecutive enrichment from  
 152 biological samples using  $\text{Fe}_3\text{O}_4@\text{PDA}@\text{UIO-66-NH}_2$ .




153

154 **Fig. S7.** Western blot results of three marker proteins (CD63, CD9 and EPCAM) in urinary  
 155 exosomes and MCF-7 cells derived exosomes.




156

157 **Fig. S8.** Western blot results of TSG101 protein in isolated urinary exosomes with first  
 158 time / third time recycled  $\text{Fe}_3\text{O}_4@\text{PDA}@ \text{UiO-66-NH}_2$  and with  $\text{Fe}_3\text{O}_4@\text{PDA}@ \text{UiO-66-}$   
 159  $\text{NH}_2$  storing for a month / 5 months.



160

161 **g. S9.** Venn diagram of three parallel enrichment experiments of urine exosomes  
 162 phosphoproteins result (a) and phosphopeptides statistics (b).



163

164 **Fig. S10.** The bubble chart about KEGG pathways of phosphoproteins from urine

165 exosomes. The closer the color is to red, the smaller the corresponding P value, and the

166 bigger the bubble, the more protein it contains.